Curently the only available blood test to tell which women are at risk of postpartum depression (PPD) is the one that ...

Newco Akribion Therapeutics GmbH has raised €8 million (US$8.3 million) in a seed round to develop a new and potent class of RNA-targeted CRISPR nucleases, which, rather than cleaving specific nucleic ...

HCW Biologics Inc. has received clearance of its IND application from the FDA to initiate a first-in-human phase I trial to ...

The U.K. Medicines and Health Care Products Regulatory Agency has provided guidance on what does and does not constitute a regulated digital mental health technology, but developers should be aware ...

As the number of mega-mergers have increased in recent years, and the purchase price of innovative companies rises, it is apparent that many lucrative buyouts fail to meet expectations, although a few ...

The first successful phase II trial in Duchenne muscular dystrophy (DMD) heart disease rolled out from Cumberland Pharmaceuticals Inc., which said top-line findings from the experiment called Fight ...

U.S. federal law is still lacking where AI is concerned, but California’s attorney general issued a bulletin that elevates the legal hazards of AI in medical use. The bulletin says that AI tools may ...

New and positive data for Maia Biotechnology Inc.’s lead candidate for a particularly deadly and advanced lung cancer propelled the stock modestly higher on Feb. 4. The pivotal phase II THIO-101 study ...

One of the proteins required for centrosome clustering is kinesin family member C1 (KIFC1/HSET), and modulation of KIFC1 stability could reduce its activity in cancer cells.

Researchers from Shenzhen University have evaluated the potential antiallergic effects of the histone acetyltransferase KAT6A inhibitor WM-1119 on IgE-mediated mast cell activation and allergic ...

Aligos Therapeutics Inc. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment ...

Japan’s drug pricing scheme has gotten more complicated, and pharma companies should brace themselves for annual price cuts.